Clinical Trials | December 19, 2025
Gilead’s new HIV therapy shows promising Phase 3 results
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The update promises to revolutionize laboratory workflows by optimizing resources
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Ryght AI tackles these hurdles with its AI Site Twin platform
This launch is part of the company's strategy to expand its nutraceutical portfolio
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Subscribe To Our Newsletter & Stay Updated
